How much does Cemiplimab cost?

Cemiplimab (Cemiplimab) is an immunotherapy drug that is widely used in the field of tumor treatment. Its main role is to enhance the immune system's attack power against certain types of cancer by inhibiting the immune checkpoint PD-1 (programmed death).

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.

The drug is particularly suitable for the treatment of advanced squamous cell non-small cell lung cancer (SCC), especially in patients with high PD-L1 (programmed death ligand -1) expression detected in the patient. PD-L1 is an immune evasion mechanism that allows cancer cells to evade attack by the immune system, but cimepilimab works by blocking PD-1 The interaction between and PD-L1 activates T lymphocytes, making them more effective in identifying and destroying cancer cells.

This treatment has achieved remarkable success in some patients, extending survival and improving quality of life. However, cimepilimab may cause some adverse effects, including fatigue, rash, nausea, diarrhea, and immune-related adverse events, such as immune thyroid disease.

Overall, cimepilimab represents an important breakthrough in oncology treatment, especially for patients for whom conventional treatments are ineffective or unsuitable. It provides a new approach that is expected to improve the effectiveness of cancer treatment and inspires extensive research and application of immunotherapy. Patients should receive treatment under physician supervision to ensure optimal efficacy and safety.